Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04883762 · ClinicalTrials.gov registry record · Phase 1

Stool Transplant to Control Treatment-related Diarrhea

A Phase 1 study of Fecal Microbiota Transplantation (FMT), sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 1
Development phase
4
Enrollment target
1
Study location

NCT04883762: Active Phase 1 study of Fecal Microbiota Transplantation (FMT), sponsored by Memorial Sloan Kettering Cancer Center.

NCT04883762 is a Phase 1 study of Fecal Microbiota Transplantation (FMT) that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04883762, a Phase 1 study of Fecal Microbiota Transplantation (FMT), is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
4 participants
Enrollment target
1
Study location

Study Summary

This study will test the safety, effectiveness, and feasibility of a treatment called fecal microbiota transplantation (FMT) to reduce the symptoms of ICI-related diarrhea. FMT uses a liquid preparation of stool collected from a healthy donor with normal (healthy) bacteria; this liquid is infused into the small or large intestine of a recipient during a colonoscopy procedure. The study researchers think that the healthy bacteria in the transplanted stool will grow and replace the unhealthy bacteria and return the intestines and colon of the recipient to a healthy state.

Primary Outcome

will be grading according to CTCAE 5.0.1

Interventions

  • BIOLOGICAL Fecal Microbiota Transplantation (FMT)

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2021-05-10
Est. Completion 2026-05
Phase Phase 1
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT04883762 still lists

NCT04883762 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Fecal Microbiota Transplantation (FMT) appearing as the primary indexed condition, and to 1 intervention - of which Fecal Microbiota Transplantation (FMT) is the first listed.

NCT04883762 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT04883762 about?

NCT04883762 is a clinical study titled "Stool Transplant to Control Treatment-related Diarrhea". This study will test the safety, effectiveness, and feasibility of a treatment called fecal microbiota transplantation (FMT) to reduce the symptoms of ICI-related diarrhea. FMT uses a liquid preparation of stool collected from a healthy donor with normal (healthy) bacteria; this liquid is infused i...

What is the current status of trial NCT04883762?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2021-05-10. Estimated completion is 2026-05.

What conditions does trial NCT04883762 study?

This clinical trial studies the following conditions: Fecal Microbiota Transplantation (FMT).

What interventions are being tested in trial NCT04883762?

The interventions under investigation include: Fecal Microbiota Transplantation (FMT) (BIOLOGICAL).

Who is sponsoring clinical trial NCT04883762?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04883762 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT04883762's enrollment target sits among peer trials

4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04883762, the US trial registry maintained by the National Library of Medicine. NCT04883762 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.